Realizing the Clinical Potential of Cancer Nanotechnology by Minimizing Toxicologic and Targeted Delivery Concerns
-
- Sanjay Singh
- Authors' Affiliations: Departments of 1Pharmacology, 2Pathology, 3Dermatology and 4Surgery, 5The Melanoma Center, and 6The Melanoma Therapeutics Program, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
-
- Arati Sharma
- Authors' Affiliations: Departments of 1Pharmacology, 2Pathology, 3Dermatology and 4Surgery, 5The Melanoma Center, and 6The Melanoma Therapeutics Program, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
-
- Gavin P. Robertson
- Authors' Affiliations: Departments of 1Pharmacology, 2Pathology, 3Dermatology and 4Surgery, 5The Melanoma Center, and 6The Melanoma Therapeutics Program, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania
書誌事項
- 公開日
- 2012-11-14
- DOI
-
- 10.1158/0008-5472.can-12-1527
- 公開者
- American Association for Cancer Research (AACR)
この論文をさがす
説明
<jats:title>Abstract</jats:title> <jats:p>Nanotechnology has the potential to make smart drugs that would be capable of targeting cancer but not normal cells and to load combinations of cooperating agents into a single nanosized particle to more effectively treat this disease. However, to realize the full potential of this technology, the negative aspects associated with these nanoparticles need to be overcome. This review discusses concerns in the field limiting realization of the full clinical potential of this technology, which are toxicity and targeted delivery. Strategies to overcome these hurdles are also reviewed, which could lead to attainment of the full clinical potential of this exciting technology. Cancer Res; 72(22); 5663–8. ©2012 AACR.</jats:p>
収録刊行物
-
- Cancer Research
-
Cancer Research 72 (22), 5663-5668, 2012-11-14
American Association for Cancer Research (AACR)